Location History:
- Mumbai, IN (2013)
- Monmouth Junction, NJ (US) (2006 - 2015)
- Kalyani Nagar, IN (2016)
- Bengaluru, IN (2015 - 2017)
- Bellandur, IN (2019)
Company Filing History:
6 out of 846 
5 out of 3,684 
Years Active: 2006-2019
Title: The Innovations of Manoj Nerurkar
Introduction
Manoj Nerurkar is a prominent inventor based in Monmouth Junction, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 11 patents. His work focuses on developing innovative formulations that address critical health issues.
Latest Patents
Among his latest patents is a formulation titled "Stable subcutaneous protein formulations and uses thereof." This invention relates to stable formulations comprising CTLA4Ig molecules, including both lyophilized and liquid formulations. These formulations are designed for administration via various routes, such as intravenous (IV) and subcutaneous (SC), aimed at treating immune system diseases and inducing tolerance. Another notable patent is the "Controlled release sterile injectable aripiprazole formulation and method." This invention provides a controlled release sterile freeze-dried aripiprazole formulation, which is designed to release the drug over a period of at least one week and up to eight weeks after intramuscular injection. The patent also includes methods for preparing this formulation and treating schizophrenia.
Career Highlights
Manoj Nerurkar has worked with several esteemed companies in the pharmaceutical industry, including Otsuka Pharmaceutical Company, Limited and Bristol-Myers Squibb Company. His experience in these organizations has contributed to his expertise in drug formulation and development.
Collaborations
Throughout his career, Manoj has collaborated with notable professionals, including Vijay H. Naringrekar and Janusz W. Kostanski. These collaborations have further enriched his work and innovations in the pharmaceutical field.
Conclusion
Manoj Nerurkar's contributions to pharmaceutical innovations are noteworthy, particularly in the development of stable formulations for critical health treatments. His extensive patent portfolio reflects his commitment to advancing medical science and improving patient care.